Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Fotivda
Pharma
BMS' Opdivo, Aveo's Fotivda fail as combo in kidney cancer
Despite failure as part of a combination with Opdivo, Aveo is touting the performance of Fotivda as a monotherapy in kidney cancer.
Kevin Dunleavy
Jul 18, 2024 4:26pm
Korean company LG Chem buys Aveo oncology drugs for $566M
Oct 18, 2022 10:17am
Aveo's tivozanib, after years of setbacks, wins its FDA nod
Mar 11, 2021 11:25am
